NIH #R37CA296642
Dysregulated Complement Pathway in Macrophage Reprogramming and Progression of HCC in MASH
Active
- Amount
- $600K–$700K
- Period
- 2024-12-10 → 2029-11-30
- PIs
- 1
Renumathy Dhanasekaran
Full Professor(heuristic)
Hepatocellular Carcinoma Treatment and Prognosis · Hepatology
Compare more Hepatology professors.
h-index60
i10-index108
Publications224
Citations44,918
Grants
2 total · 1 active
NIH #K08CA222676
Functional Proteomic Analysis and Biomarker Identification in a Novel Mouse Model of Metastatic Hepatocellular Carcinoma (HCC)
- Amount
- $200K–$300K
- Period
- 2018-07-09 → 2023-06-30
- PIs
- 1
Active grants are a starting point, not proof of an opening. Confirm recruiting and funding with the professor, current students, and your written offer. Learn how to verify PhD funding →
Recent Public Signals
- New preprint: A Novel Niclosamide Sulfate Prodrug with Enhanced Bioavailability Suppresses Hepatocellular Carcinoma via Inhibition of Multiple Signaling Pathways2026-03-10
- New paper: Unraveling the tapestry: Lessons from multi-omics and spatial biology in hepatocellular cancer (Hepatology)2026-02-12
- New NIH award: Dysregulated Complement Pathway in Macrophage Reprogramming and Progression of HCC in MASH2024-12-10
Are you this professor?
No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.
Data Freshness
- Publications as of 2026-07-09
- Grants as of 2026-09-03
Data may not be current
Find elsewhere
ORCID: 0000-0001-8819-7511